Cargando…
CAR‐NK cells from engineered pluripotent stem cells: Off‐the‐shelf therapeutics for all patients
Clinical success of adoptive cell therapy with chimeric antigen receptor (CAR) T cells for treating hematological malignancies has revolutionized the field of cellular immunotherapy. However, due to the nature of utilizing autologous T cells, affordability and availability are major hurdles, in addi...
Autores principales: | Lu, Shi‐Jiang, Feng, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560199/ https://www.ncbi.nlm.nih.gov/pubmed/34724715 http://dx.doi.org/10.1002/sctm.21-0135 |
Ejemplares similares
-
Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021) -
Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer
por: Montagner, Isabella Monia, et al.
Publicado: (2020) -
Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020) -
Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
por: Cutmore, Lauren C., et al.
Publicado: (2021) -
Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL
por: Ureña-Bailén, Guillermo, et al.
Publicado: (2022)